Suchergebnisse - "Wickremsinhe, Enaksha R"

PubPharm (7)

1

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

enthalten in: Oncology | 2016

von Calvo, E. | Braiteh, F. | Von Hoff, D. | +11

2

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2015

von Faivre, S. | Olszanski, A. | Weigang-Köhler, K. | +10

3

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2014

von Salazar, R. | Morales, S. | Gil-Martín, M. | +7

4

High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS

enthalten in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2013

von Wickremsinhe, E. | Lee, L. | Schmalz, C. | +2

5

Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts

enthalten in: Molecular cancer therapeutics | 2013

von Pratt, S. | Durland-Busbice, S. | Shepard, R. | +5

6

Pharmacogenomics of gemcitabine metabolism : functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2013

von Baker, J. | Wickremsinhe, E. | Li, C. | +7

7

Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement

enthalten in: Analytical chemistry | 2010

von Wickremsinhe, E. | Lutzke, B. | Jones, B. | +5

1
[1]